共查询到16条相似文献,搜索用时 87 毫秒
1.
鼠疫F1-V重组融合蛋白抗原的制备及其免疫保护效果的研究 总被引:2,自引:0,他引:2
为制备鼠疫耶尔森氏菌F1-V重组融合蛋白抗原,观察其免疫原性和免疫保护效果,通过疏水层析、阴离子交换层析、凝胶过滤层析纯化鼠疫F1-V重组融合蛋白抗原.用氢氧化铝凝胶吸附制备试验性鼠疫F1-V重组融合蛋白抗原,皮下接种健康BALB/c小鼠,ELISA检测血清F1-V抗体效价、MTT法测定淋巴细胞增殖能力,进一步用400LD50鼠疫耶尔森氏菌141标准毒株皮下攻毒,观察动物的存活情况.通过三步柱层析纯化获得的鼠疫F1-V重组融合蛋白抗原纯度达到90%以上.氢氧化铝凝胶吸附的鼠疫F1-V重组融合蛋白抗原免疫BALB/c小鼠三次,血清抗F1-V抗体效价为1∶(51200±800),对耶尔森氏菌141强毒株攻击的保护率是90%.上述结果表明,制备的鼠疫F1-V重组融合蛋白抗原具有良好的免疫原性和免疫保护效果,为研制鼠疫F1-V重组融合蛋白疫苗奠定了基础. 相似文献
2.
3.
在此实验中, 设计了一种包含2种成分的重组融合蛋白作为疫苗成分来防护鼠疫耶尔森氏菌(Yersinia)可能产生的生物威胁. 重组F1-V蛋白与铝佐剂结合, 分别以10, 20, 50 mg剂量免疫BALB/C小鼠, 周期为2个月. 检测小鼠血清抗体水平和T辅助细胞的亚型. 免疫后小鼠以25~600 LD50剂量的鼠疫耶尔森氏菌141强毒株进行皮下攻毒实验. 结果证明, F1-V重组蛋白在 小鼠体内诱导产生足够保护的免疫应答. 血清IgG水平是产生最终保护力的一个重要因素. 20 μg的免疫剂量可以诱导血清抗体效价高达51200, 使小鼠对400 LD50的鼠疫耶尔森氏菌产生100%的保护. F1-V重组蛋白引发的抗体亚型主要为IgG1类, 说明抗体反应趋向Th2型反应. 流式细胞分析表明, 铝佐剂主要帮助F1-V重组融合蛋白诱导强烈的体液免疫而不是CTL细胞免疫应答.表明F1-V重组亚单位疫苗株有希望成为一种新型的鼠疫疫苗候选株. 相似文献
4.
5.
目的:在大肠杆菌中表达、纯化无标签鼠疫耶尔森菌低钙反应V抗原突变体,并对其免疫原性进行研究。方法:采用融合PCR方法将V抗原基因中编码半胱氨酸的碱基缺失突变,将获得得V抗原突变体基因克隆到原核表达载体pET32a(+)后转化大肠杆菌BL21(DE3),用IPTG诱导表达并进行柱层析纯化,纯化产物以Western印迹进行鉴定并免疫BALB/c小鼠,通过ELISA检测免疫血清效价。结果:目的蛋白在大肠杆菌中获得了可溶性高表达,经三步柱层析后纯度高于95%,经Western印迹检测可与野生型V抗原单克隆抗体特异性结合,免疫小鼠后获得高效价免疫血清。结论:获得了无标签的鼠疫耶尔森菌V抗原突变体蛋白,并证实其具有免疫原性,将对V抗原结构和功能的研究提供帮助。 相似文献
6.
目的:在大肠杆菌中表达、纯化无标签鼠疫耶尔森菌低钙反应V抗原突变体,并对其免疫原性进行研究。方法:采用融合PCR方法将Ⅴ抗原基因中编码半胱氨酸的碱基缺失突变,将获得得Ⅴ抗原突变体基因克隆到原核表达载体pET32a(+)后转化大肠杆菌BL21(DE3),用IPTG诱导表达并进行柱层析纯化,纯化产物以Western印迹进行鉴定并免疫BALB/c小鼠,通过ELISA检测免疫血清效价。结果:目的蛋白在大肠杆菌中获得了可溶性高表达,经三步柱层析后纯度高于95%,经Western印迹检测可与野生型V抗原单克隆抗体特异性结合,免疫小鼠后获得高效价免疫血清。结论:获得了无标签的鼠疫耶尔森菌Ⅴ抗原突变体蛋白,并证实其具有免疫原性,将对V抗原结构和功能的研究提供帮助。 相似文献
7.
王婷 《微生物学免疫学进展》2012,40(2):58-65
鼠疫菌F1抗原是鼠疫亚单位新疫苗最重要的候选抗原,对其性质的充分认识,将有助于抗原制造工艺和新疫苗的开发。F1抗原的性质研究包括:微观结构,一级核苷酸、氨基酸序列,二级结构,高分子聚集形态,以及F1抗原的理化性质。 相似文献
8.
重组鼠疫菌F1抗原在大肠杆菌中的表达及免疫原性分析 总被引:2,自引:0,他引:2
利用基因重组技术,用pET42(b+)质粒在大肠杆菌DE3中表达鼠疫菌F1抗原。经分析rF1抗原基因序列与天然F1抗原结构基因序列完全一致,电泳扫描测其表达量为25%:W estern B lot结果表明,rF1抗原可与F1特异性抗体相互作用,具有天然F1抗原的活性。用镍离子亲和层析纯化rF1抗原免疫BALB/c小鼠,在其血清中可检测到高滴度的抗F1抗体。 相似文献
9.
为获得含有鼠疫F1和V抗原编码基因以及人tPA信号肽基因的重组质粒tPA-pVAX1/F1-V,并测定其诱导特异性免疫应答的能力, 用PCR扩增鼠疫菌F1和V编码基因,分别与pGEM-T连接测序,构建pVAX1/F1-V融合重组质粒.PCR扩增tPA信号肽片段并将其插入到F1-V的上游,构建tPA-pVAX1/F1-V融合重组质粒;转染COS-7细胞,Western blot法鉴定目的蛋白的表达.重组质粒tPA-pVAX1/F1-V加GM-CSF佐剂免疫BALB/c小鼠,观察免疫效果.400个LD50强毒鼠疫菌皮下攻毒观察保护率.结果表明,tPA-pVAX1/F1-V在COS-7细胞中表达;免疫鼠体内产生特异性抗体;抗体亚型分析、细胞因子等指标的测定表明,所构建DNA疫苗以诱发Th1型免疫为主;61472;攻毒保护率达90%.结果提示,已成功构建F1-V融合蛋白真核表达载体tPA-pVAX1/F1-V,且具有诱导特异性细胞免疫和体液免疫应答的能力, 对强毒鼠疫菌皮下攻毒有一定的保护效力,为鼠疫菌新型疫苗研制奠定了基础. 相似文献
10.
从表达rF1抗原的大肠杆菌中以Superdex-200凝胶过滤层析纯化rF1抗原,电泳扫描显示纯化率>90%。SDS-PAGE及琼脂免疫双扩散结果显示纯化的rF1抗原具天然F1抗原的活性。将此纯化的rF1抗原用于间接ELISA分析免疫动物血清中抗F1抗体的水平,并与天然F1抗原相比较,证明rF1抗原优于天然F1抗原分析结果,可用于鼠疫的血清学检测。 相似文献
11.
In this study, we designed and engineered a two-component recombinant fusion protein antigen as a vaccine candidate against the possible biological threat of Yersinia pestis. The recombinant F1-V pro-tein was formulated with Alhydrogel. A four-time injection with a dosage of 10, 20 and 50 μg/mouse in about two months was adopted for vaccination. Serum antibodies and subclass of T helper cells were measured and analyzed. After the final vaccination, the mice were challenged by 141 strain with 25― 600 LD50. In conclusion, the recombinant vaccine was capable of inducing protective immunity against subcutaneous challenge. The level of serum IgG was supposed to be a main factor that affected the final protection of challenge. 20 μg recombinant protein could induce an endpoint titre of serum IgG as high as 51200, which was enough to afford 100% protection against 400 LD50 virulent 141 challenge. The antibody isotype analysis showed that the vaccine induced predominantly an IgG1 rather than IgG2a response. Flow cytometric analysis revealed that Alhydrogel significantly helped induce a stronger humoral immunity instead of CTL cellular response. These findings suggested that the plague F1-V subunit vaccine is promising for the next plague vaccine. 相似文献
12.
Protection against lethal subcutaneous challenge of virulent <Emphasis Type="Italic">Y. pestis</Emphasis> strain 141 using an F1-V subunit vaccine
下载免费PDF全文
![点击此处可从《中国科学C辑(英文版)》网站下载免费的PDF全文](/ch/ext_images/free.gif)
In this study, we designed and engineered a two-component recombinant fusion protein antigen as a vaccine candidate against
the possible biological threat of Yersinia pestis. The recombinant F1-V protein was formulated with Alhydrogel. A four-time injection with a dosage of 10, 20 and 50 μg/mouse
in about two months was adopted for vaccination. Serum antibodies and subclass of T helper cells were measured and analyzed.
After the final vaccination, the mice were challenged by 141 strain with 25–600 LD50. In conclusion, the recombinant vaccine was capable of inducing protective immunity against subcutaneous challenge. The level
of serum IgG was supposed to be a main factor that affected the final protection of challenge. 20 μg recombinant protein could
induce an endpoint titre of serum IgG as high as 51200, which was enough to afford 100% protection against 400 LD50 virulent 141 challenge. The antibody isotype analysis showed that the vaccine induced predominantly an IgG1 rather than IgG2a
response. Flow cytometric analysis revealed that Alhydrogel significantly helped induce a stronger humoral immunity instead
of CTL cellular response. These findings suggested that the plague F1-V subunit vaccine is promising for the next plague vaccine. 相似文献
13.
14.
Liu WT Hsu HL Liang CC Chuang CC Lin HC Liu YT 《FEMS immunology and medical microbiology》2007,51(1):58-69
We investigated the relative immunogenicity and protective efficacy of recombinant X85MF1 and X85V strains of DeltacyaDeltacrpDeltaasd-attenuated Salmonella Typhimurium expressing, respectively, secreted Yersinia pestis F1 and V antigens, following intranasal (i.n.) or i.n. combined with oral immunization for a mouse model. A single i.n. dose of 10(8) CFU of X85MF1 or X85V induced appreciable serum F1- or V-specific IgG titres, although oral immunization did not. Mice i.n. immunized three times (i.n. x 3) with Salmonella achieved the most substantial F1/V-specific IgG titres, as compared with corresponding titres for an oral-primed, i.n.-boosted (twice; oral-i.n. x 2) immunization regimen. The level of V-specific IgG was significantly greater than that of F1-specific IgG (P<0.001). Analysis of the IgG antibodies subclasses revealed comparable levels of V-specific Th-2-type IgG1 and Th-1-type IgG2a, and a predominance of F1-specific Th-1-type IgG2a antibodies. In mice immunized intranasally, X85V stimulated a greater IL-10-secreting-cell response in the lungs than did X85MF1, but impaired the induction of gamma-interferon-secreting cells. A program of i.n. x 3 and/or oral-i.n. x 2 immunization with X85V provided levels of protection against a subsequent lethal challenge with Y. pestis, of, respectively, 60% and 20%, whereas 80% protection was provided following the same immunization but with X85MF1. 相似文献
15.
摘要:【目的】利用大肠杆菌BL21λDE3的表达系统,表达出有活性的鼠疫耶尔森氏菌(以下简称鼠疫菌)调控子蛋白H-NS,为进一步研究H-NS的转录调控奠定基础。【方法】 PCR扩增鼠疫菌201株hns基因的编码区,将其直接克隆入pET28a质粒中,再将pET28a-hns重组质粒转入大肠杆菌BL21λDE3菌株中,所得菌株经IPTG诱导后能表达出鼠疫菌His-H-NS蛋白;通过体外的凝胶迁移实验(EMSA)和DNaseⅠ足迹实验对His-H-NS蛋白与DNA的结合活性进行分析。【结果】成功表达出有活性的鼠疫菌His-H-NS蛋白,该蛋白对鼠疫菌pH6抗原基因(psaA、psaE)及rovA基因均有结合活性。【结论】鼠疫菌His-H-NS具有DNA结合活性,说明H-NS能调控鼠疫菌基因的转录。 相似文献
16.
目的对兰州生物制品研究所有限责任公司研制的鼠疫菌F1抗体酶联免疫诊断试剂盒和鼠疫菌F1抗原酶联免疫诊断试剂盒进行临床应用评价。方法采用双抗原/抗体夹心酶联免疫吸附试验(ELISA)、间接血球凝集试验(IHA)、胶体金免疫层析试验(GICA)3种方法的诊断试剂对比检测云南省地方病防治所中心实验室保藏的和现场采集的血清样品和脏器样品,对血清样品做鼠疫菌F1抗体检测,对脏器样品做鼠疫菌F1抗原检测。结果在358份血清样品中,ELISA试剂检出F1抗体阳性52份(14.52%),IHA试剂检出阳性37份(10.34%),GICA试剂检出阳性45份(12.57%)。ELISA与IHA试剂的符合率为95.23%,与GICA试剂的符合率为96.92%。经统计学χ2检验,ELISA试剂检出F1抗体阳性率高于IHA试剂(χ2=11.53,P=0.000 7),与GICA试剂检出的差异无统计学意义(χ2=3.27,P=0.070 4)。进一步分析滴度差值频数,ELISA试剂检测人血清的敏感性高于IHA试剂的样品占87.5%。在117份脏器样品中,3种试剂均检出F1抗原阳性15份(12.82%),符合率100%。滴度差值频数比较,ELISA试剂检测敏感性高于反向间接血球凝集试验(RIHA)试剂的样品为78.57%。结论兰州生物制品研究所有限责任公司研制的鼠疫菌F1抗体酶联免疫诊断试剂盒和鼠疫菌F1抗原酶联免疫诊断试剂盒性质特异,其敏感性优于IHA试剂盒和GICA试剂条,值得在鼠疫的监测和快速诊断中推广应用。 相似文献